hiv associated lipodystrophy market

DelveInsight's "HIV-associated Lipodystrophy Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the HIV-associated Lipodystrophy, historical and forecasted epidemiology as well as the HIV-associated Lipodystrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The HIV-associated Lipodystrophy market report provides current treatment practices, emerging drugs, HIV-associated Lipodystrophy market share of the individual therapies, current and forecasted HIV-associated Lipodystrophy market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current HIV-associated Lipodystrophy treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the HIV-associated Lipodystrophy market.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

HIV-associated Lipodystrophy Disease Understanding and Treatment Algorithm

The DelveInsight’s HIV-associated Lipodystrophy market report gives a thorough understanding of the HIV-associated Lipodystrophy by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.

HIV-associated Lipodystrophy Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for HIV-associated Lipodystrophy.

HIV-associated Lipodystrophy Treatment

It covers the details of conventional and current medical therapies available in the HIV-associated Lipodystrophy market for the treatment of the condition. It also provides HIV-associated Lipodystrophy treatment algorithms and guidelines in the United States, Europe, and Japan.

HIV-associated Lipodystrophy Epidemiology 

The HIV-associated Lipodystrophy epidemiology section provides insights about the historical and current HIV-associated Lipodystrophy patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the HIV-associated Lipodystrophy market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted HIV-associated Lipodystrophy epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- HIV-associated Lipodystrophy Epidemiology

The epidemiology segment also provides the HIV-associated Lipodystrophy epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

HIV-associated Lipodystrophy Recent Developments

• In April 2025, Theratechnologies Inc. announced that the FDA approved its Prior Approval Supplement for EGRIFTA SV® (tesamorelin), the only U.S.-approved treatment to reduce excess abdominal fat in adults with HIV-associated lipodystrophy.
• In March 2025, Theratechnologies announced that the FDA approved its supplemental Biologics License Application (sBLA) for the F8 formulation of tesamorelin for injection, to be marketed as EGRIFTA WR™. Tesamorelin is the only FDA-approved medication for reducing excess abdominal fat in adults with HIV-related lipodystrophy.

HIV-associated Lipodystrophy Drug Chapters

The drug chapter segment of the HIV-associated Lipodystrophy report encloses the detailed analysis of HIV-associated Lipodystrophy marketed drugs and late-stage (Phase-III and Phase-II) HIV-associated Lipodystrophy pipeline drugs. It also helps to understand the HIV-associated Lipodystrophy clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

HIV-associated Lipodystrophy Marketed Drugs

The report provides the details of the marketed products/off-label treatments available for HIV-associated Lipodystrophy treatment.

HIV-associated Lipodystrophy Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for HIV-associated Lipodystrophy treatment.

HIV-associated Lipodystrophy Market Outlook

The HIV-associated Lipodystrophy market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted HIV-associated Lipodystrophy market trends by analyzing the impact of current HIV-associated Lipodystrophy therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of HIV-associated Lipodystrophy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated HIV-associated Lipodystrophy market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the HIV-associated Lipodystrophy market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Findings

This section includes a glimpse of the HIV-associated Lipodystrophy market in 7MM.

The United States Market Outlook

This section provides the total HIV-associated Lipodystrophy market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total HIV-associated Lipodystrophy market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total HIV-associated Lipodystrophy market size and market size by therapies in Japan is also mentioned.

HIV-associated Lipodystrophy Drugs Uptake

This section focuses on the rate of uptake of the potential HIV-associated Lipodystrophy drugs recently launched in the HIV-associated Lipodystrophy market or expected to get launched in the market during the study period 2019-2032. The analysis covers HIV-associated Lipodystrophy market uptake by drugs; patient uptake by therapies; and sales of each drug.   

HIV-associated Lipodystrophy Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of HIV-associated Lipodystrophy market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

HIV-associated Lipodystrophy Pipeline Development Activities

The HIV-associated Lipodystrophy report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses HIV-associated Lipodystrophy key players involved in developing targeted therapeutics.

Pipeline Development Activities

The HIV-associated Lipodystrophy report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for HIV-associated Lipodystrophy emerging therapies.

Reimbursement Scenario in HIV-associated Lipodystrophy

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current HIV-associated Lipodystrophy market trends, we take KOLs and SMEs ' opinion working in the HIV-associated Lipodystrophy domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or HIV-associated Lipodystrophy market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the HIV-associated Lipodystrophy Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of HIV-associated Lipodystrophy, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the HIV-associated Lipodystrophy epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for HIV-associated Lipodystrophy is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the HIV-associated Lipodystrophy market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global HIV-associated Lipodystrophy market

Report Highlights

• In the coming years, the HIV-associated Lipodystrophy market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence HIV-associated Lipodystrophy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• Major players are involved in developing therapies for HIV-associated Lipodystrophy. The launch of emerging therapies will significantly impact the HIV-associated Lipodystrophy market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for HIV-associated Lipodystrophy
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

HIV-associated Lipodystrophy Report Insights

• HIV-associated Lipodystrophy Patient Population
• Therapeutic Approaches
• HIV-associated Lipodystrophy Pipeline Analysis
• HIV-associated Lipodystrophy Market Size and Trends
• HIV-associated Lipodystrophy Market Opportunities
• Impact of upcoming HIV-associated Lipodystrophy Therapies

HIV-associated Lipodystrophy Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• HIV-associated Lipodystrophy Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

HIV-associated Lipodystrophy Report Assessment

• Current Treatment Practices
• Unmet Needs
• HIV-associated Lipodystrophy Pipeline Product Profiles
• HIV-associated Lipodystrophy Market Attractiveness
• Market Drivers and Barriers

Key Questions

Market Insights:

• What was the HIV-associated Lipodystrophy drug class share (%) distribution in 2019 and how it would look like in 2032?
• What would be the HIV-associated Lipodystrophy total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest HIV-associated Lipodystrophy market size during the forecast period (2019-2032)?
• At what CAGR, the HIV-associated Lipodystrophy market is expected to grow by 7MM during the forecast period (2019-2032)?
• What would be the HIV-associated Lipodystrophy market outlook across the 7MM during the forecast period (2019-2032)?
• What would be the HIV-associated Lipodystrophy market growth till 2032, and what will be the resultant market Size in the year 2032?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of the HIV-associated Lipodystrophy?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical HIV-associated Lipodystrophy patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of HIV-associated Lipodystrophy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to HIV-associated Lipodystrophy?
• Out of all 7MM countries, which country would have the highest prevalent population of HIV-associated Lipodystrophy during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the HIV-associated Lipodystrophy treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of HIV-associated Lipodystrophy in the USA, Europe, and Japan?
• What are the HIV-associated Lipodystrophy marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of HIV-associated Lipodystrophy?
• How many therapies are in-development by each company for HIV-associated Lipodystrophy treatment?
• How many are emerging therapies in mid-stage, and late stage of development for HIV-associated Lipodystrophy treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the HIV-associated Lipodystrophy therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for HIV-associated Lipodystrophy and their status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for HIV-associated Lipodystrophy?
• What are the global historical and forecasted market of HIV-associated Lipodystrophy?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the HIV-associated Lipodystrophy market
• To understand the future market competition in the HIV-associated Lipodystrophy market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for HIV-associated Lipodystrophy in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for HIV-associated Lipodystrophy market
• To understand the future market competition in the HIV-associated Lipodystrophy market